Cellectis Nom. buy spalato
Summary
This prediction ended on 14.09.15 with a price of €29.00. The price of Cellectis Nom. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.55%. spalato has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Cellectis Nom. | -2.037% | -2.037% | 31.349% | -84.798% |
iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by spalato for this prediction
In the thread Cellectis Nom. diskutieren
Sehr interresant
ellectis is an international pharmaceutical company headquartered in Paris, France. It is focused on developing and offering immunotherapies based on gene-edited CAR-T cells (UCART). Unlike other companies in the CAR-T space, Cellectis offers allogeneic CAR-T cells, which allows it to produce an off-the-shelf alternative. The company plans to utilize its validated genome-editing technology to delete the T-cell receptor (TCR) from CAR-T cells. By deleting the TCR, the CAR-T cells are no longer able to detect "non-self", thus theoretically allowing T-cells from unrelated donors to be transplanted into recipients without the risk of graft-versus-host disease. This allogeneic cell production can be standardized and controlled, while autologous cells cannot, because they are sampled from individual patients. The company has a Phase I clinical trial using anti-CD19 CAR-T cells to treat ALL and CLL planned to start in Q2 2015.
Cellectis has two major big pharma partners - Servier Laboratories and Pfizer (NYSE:PFE), which provide clinical and regulatory expertise. Under the Pfizer collaboration announced in June 2014, Cellectis received $80M, funding for Pfizer-selected CAR-T targets, and up to $185M in milestones from eachcandidate Pfizer develops (~12 targets), and then finally, tiered royalties on any future sales. The cash and support from the Servier/Pfizer partnerships serve to buffer both financial and development risks moving forward. Cellectis currently has a market cap of $803.74M, $20.21M in cash, and a quarterly burn of $2M.